Pivotal Research analyst Timothy Ramey maintained a Buy rating on USANA Health (NYSE: USNA) today and set a price target of $135. The company’s shares opened today at $111.78.
Ramey commented:
“WeChat platform to Chinese-speaking customers, fueled growth. We suspect this will have a broader positive impact as a large percentage of Associates outside of China speak and run their business in Chinese. This market will strengthen further in the 4Q with a full quarter of these impacts plus the positive impacts of the in Macau. This will be the first conference where products are sold at the meeting; the company expects $8- $12 million of sales incremental to the meeting.”
According to TipRanks.com, Ramey is a 5-star analyst with an average return of 11.3% and a 63.2% success rate. Ramey covers the Consumer Goods sector, focusing on stocks such as Constellation Brands Inc, Post Holdings Inc, and Brown-Forman B.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for USANA Health with a $135 average price target.
See today’s analyst top recommended stocks >>
Based on USANA Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $33.91 million. In comparison, last year the company had a net profit of $23.77 million.
Based on the recent corporate insider activity of 92 insiders, corporate insider sentiment is negative on the stock. Most recently, in July 2018, Gilbert Fuller, a Director at USNA sold 282 shares for a total of $37,004.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
USANA Health Sciences, Inc. develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, and Sense-beautiful science.
